Close

AMAG (AMAG) Shares Collapse as Board Quietly Abandons Active Sale Process

May 10, 2012 12:41 PM EDT
Shares of AMAG Pharma (Nasdaq: AMAG) are getting sold Thursday as investors are responding to news the company will shift its "focus from an active sale process to the continued growth of Feraheme and the pursuit of business development opportunities."

The development was issued in a release which disclosed the appointment of William Heiden as the company's new President and CEO. Sneaky.

Analysts at both Baird and Ladenburg Thalmann downgraded shares of AMAG amid the news.

The stock last traded at $13.87, down about 13.4 percent from Wednesday's closing price.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Corporate News, Insiders' Blog

Related Entities

Robert W Baird, Ladenburg Thalmann Financial Services